Lisaftoclax



Cat. No.:	HY-129179		
CAS No.:	2180923-05-9		
Molecular Formula:	$C_{45}H_{48}ClN_7O_8S$		
Molecular Weight:	882.42		
Target:	Bcl-2 Family		
Pathway:	Apoptosis		
Storage:	Powder	-20°C	3 years
		4°C	2 years
	In solvent	-80°C	6 months
		-20°C	1 month

SOLVENT & SOLUBILITY

In Vitro

DMSO : 100 mg/mL (113.32 mM; Need ultrasonic)

Preparing Stock Solutions	Solvent / Mass / Concentration	1 mg	5 mg	10 mg
	1 mM	1.1332 mL	5.6662 mL	11.3325 mL
	5 mM	0.2266 mL	1.1332 mL	2.2665 mL
	10 mM	0.1133 mL	0.5666 mL	1.1332 mL

Please refer to the solubility information to select the appropriate solvent.

In Vivo

1. Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)
   Solubility: 2.5 mg/mL (2.83 mM); Suspended solution; Need ultrasonic

BIOLOGICAL ACTIVITY

Description

Lisaftoclax (compound 6) is a dual Bcl-2 and Bcl-xl inhibitor with anti-tumor activity, extracted from patent WO2018027097A1. Lisaftoclax exhibits IC_{50} values of 2 nM and 5.9 nM for Bcl-2 and Bcl-xl, respectively[1].

IC_{50} & Target

Bcl-2	Bcl-xL
2 nM (IC_{50})	5.9 nM (IC_{50})

In Vitro

Lisaftoclax (compound 6) exhibits IC_{50} values of 5.5 nM and 6.4 nM in Bcl-2 dependent RS4;11 cells and Bcl-xl dependent Molm13 cells[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

REFERENCES

[1]. WANG, Chia, et al. N-(PHENYLSULFONYL)BENZAMIDES AND RELATED COMPOUNDS AS BCL-2 INHIBITORS. Patent. WO2018027097A1.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com
Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA